Therapy after acute myocardial infarction offers the prospect of incre
ased survival in carefully selected patients. Current recommendations
favor the use of beta blockers and antiplatelet agents, but some posit
ive effects have been seen with use of anticoagulants, angiotensin-con
verting enzyme inhibitors, and calcium channel blockers. Further studi
es are needed to evaluate these drug classes in reinfarction prophylax
is and to define differences among the agents in each class.